What are PCSK9 inhibitors? 

PCSK9 inhibitors are a class of advanced, injectable medications used to dramatically lower LDL (bad) cholesterol. They work by blocking a specific protein in the liver called Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). By inhibiting this protein, the medication allows the liver to clear significantly more cholesterol from the bloodstream than would be possible with standard oral medications alone. These treatments are typically reserved for individuals with very high-risk conditions, such as Familial Hypercholesterolaemia (FH), or those who have already suffered a heart attack and cannot reach their targets with statins. 

What We’ll Discuss in This Article 

• The biological mechanism: How blocking the PCSK9 protein saves LDL receptors. 

• The difference between monoclonal antibodies (injectables) and oral tablets. 

• Clinical effectiveness: Achieving a 50% to 60% reduction in LDL. 

• Eligibility criteria: Who can access these treatments on the NHS. 

• Common side effects and the convenience of fortnightly dosing. 

• The role of PCSK9 inhibitors in “multi-drug” therapy for FH. 

• Using the BMI Calculator to support your long-term heart health plan. 

How PCSK9 Inhibitors Work 

To understand these drugs, you first have to understand the liver’s “cleaning” system. Your liver has LDL receptors on its surface that act like tiny hooks, pulling “bad” cholesterol out of the blood. Normally, the PCSK9 protein in your body attaches to these receptors and marks them for destruction. 

When you take a PCSK9 inhibitor, it neutralises that protein. This means your LDL receptors are not destroyed and can return to the surface of the liver to clear more cholesterol. 

By keeping these receptors active, the liver becomes an incredibly efficient filter. Clinical data shows that PCSK9 inhibitors can lower LDL cholesterol by 50% to 60%, even in patients already taking the maximum dose of a high-intensity statin. 

Types of PCSK9 Inhibitors 

In the UK, there are two primary monoclonal antibodies currently used: 

1. Alirocumab (Praluent) 

2. Evolocumab (Repatha) 

Both are administered as self-injections using a pre-filled “pen,” similar to an insulin pen. They are usually taken once every two weeks or once a month. Because they are proteins themselves, they cannot be taken as a pill because the stomach would simply digest them before they could reach the liver. 

Feature	Statins	PCSK9 Inhibitors
Administration	Daily Tablet	Fortnightly/Monthly Injection
Mechanism	Blocks cholesterol production.	Increases cholesterol clearance.
LDL Reduction	30% – 50%	50% – 60%
Primary Use	General high risk / First-line.	Extreme risk / Genetic FH.

Who is Eligible for Treatment? 

Because these are high-cost medications, the NHS has specific criteria for who can receive them. They are generally prescribed by a specialist at a lipid clinic rather than a GP. You may be eligible if: 

• You have Familial Hypercholesterolaemia (FH): And your cholesterol remains high despite other treatments. 

• Secondary Prevention: You have established heart disease (like a previous heart attack or stroke) and your LDL is still above a certain threshold (usually 2.6 mmol/L) despite the highest possible dose of statins. 

• Statin Intolerance: You are at very high risk and have a proven, clinical inability to take statins due to severe side effects. 

Side Effects and Safety 

PCSK9 inhibitors are remarkably well-tolerated because they are highly targeted. Unlike statins, they do not generally cause muscle aches or affect liver enzymes. 

• Injection Site Reactions: The most common side effect is slight redness, itching, or swelling where the needle entered the skin. 

• Cold-like Symptoms: Some people report a sore throat or a runny nose shortly after the injection. 

• Long-term Safety: Because these drugs are relatively new compared to statins, long-term data continues to be monitored, but so far, they show an excellent safety profile with no evidence of cognitive issues or increased diabetes risk. 

Causes and Triggers for Success 

For these advanced therapies to be most effective, several triggers must be managed: 

• The Consistency Trigger: Because the injections are only every two weeks, it is easy to forget a dose. Using a phone reminder or a calendar is essential to keep your levels stable. 

• The Cold Chain: These medications must be stored in the fridge. Injecting them while “cold” can be slightly more uncomfortable, so most patients let the pen reach room temperature for 30 minutes before use. 

• Combined Therapy: They are most effective when used with a statin, as the two drugs attack the problem from completely different biological angles. 

To Summarise 

PCSK9 inhibitors are a breakthrough in cholesterol management, offering a powerful way to clear LDL from the blood for those at the highest risk. By blocking the protein that destroys the liver’s LDL receptors, these injections can achieve results that oral medications alone cannot. While reserved for specific high-risk groups and genetic conditions like FH, they represent a vital tool in preventing heart attacks and strokes in patients who previously had few options. 

If you experience sudden, crushing chest pain, difficulty breathing, or sudden weakness on one side of your body, call 999 immediately. 

You may find our free BMI Calculator helpful for monitoring your progress, as maintaining a healthy weight remains a key pillar in reducing your overall cardiovascular risk alongside your medication. 

Authority Snapshot 

Dr. Rebecca Fernandez is a physician with experience in cardiology and internal medicine. This guide is based on established clinical standards regarding the management of high-risk lipid disorders and the use of advanced monoclonal antibody therapies.